Bal Pharma Board Approves Q2 FY27 Unaudited Financial Results

Bal Pharma Limited's Board of Directors convened on November 11, 2026, to approve the unaudited financial results (Standalone and Consolidated) for the second quarter and half-year ended September 30, 2026. The board also reviewed the limited review report from the statutory auditors, which expressed an unmodified opinion. Additionally, the board reviewed a statement confirming no deviation in the utilization of proceeds from a preferential issue of warrants for the quarter ended September 30, 2026.